Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Gene Therapy Focus

Explore the latest updates and expert interviews
Latest Videos Videos by Disease CAR-T Therapy Conferences Podcasts Features

Welcome to the Gene Therapy Focus

Explore the latest in this field by hematological disease type, showcasing expert interviews and discussions, podcasts and more.

The Gene Therapy Channel covers a variety of therapy types, with a focus on CAR-T therapy and other genome-editing techniques, including CRISPR-Cas9.

Videos by Disease

Multiple Myeloma
Lymphoma
Non-Malignant
AML
CLL
ALL
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
View All Videos
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
View All Videos
2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:54
CAR-Tregs hold potential for the treatment of autoimmune disease
Matteo Doglio • 16 Feb 2024
2:29
The importance of a multidisciplinary team when treating autoimmune disease with CAR T-cell therapy
Raffaella Greco • 2 Feb 2024
View All Videos
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
2:29
Epitope editing enables the use of novel immunotherapies for AML
Pietro Genovese • 19 Feb 2024
View All Videos
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter’s transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:49
The management of Richter’s transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023
3:07
Advancing treatment for patients with Richter’s transformation
Toby Eyre • 29 Nov 2023
3:20
Long-term outcomes from key clinical trials presented at ASH 2023
Manali Kamdar • 11 Dec 2023
View All Videos
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
View All Videos

Conferences

EBMT 2024
CAR-T Meeting 2024
ASH 2023
IMS 2023
COSTEM 2023
iwCLL 2023
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
View All Videos
4:31
T2Evolve: identifying and addressing the needs and gaps in CAR-T therapy
Carmen Sanges • 29 Feb 2024
6:06
The role of AI in medicine and how acceptance and trust in AI strategies can be fostered
Carmen Sanges • 29 Feb 2024
3:54
KCAT19: an off-the-shelf cord blood-derived allogeneic CAR-T product without genome editing
Giulia Agliardi • 26 Feb 2024
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
View All Videos
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:49
Results of a Phase I trial investigating CYNK-001, a placental NK-cell product, in patients with AML
Eunice Wang • 10 Dec 2023
0:48
The issue of short-lived treatment responses in heavily pretreated patients with ALL
Britta Vormoor • 10 Dec 2023
View All Videos
2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
2:00
Defining and treating high-risk multiple myeloma
Frits van Rhee • 28 Sep 2023
3:30
Time-dependent prognostic value of MRD assessments after ide-cel in patients with myeloma
Bruno Paiva • 29 Sep 2023
View All Videos
1:46
Emerging options for patients with MCL who relapse after a frontline BTKi
Georg Hess • 20 Oct 2023
1:51
Addressing the benefits and drawbacks of academic CAR-T cells
Christian Chabannon • 21 Oct 2023
1:06
Assessing metabolic tumor volume as a prognostic marker before CAR-T therapy for DLBCL
Michael Bishop • 21 Oct 2023
2:13
Debating whether CAR-T cells are replacing autoSCT in the treatment of autoimmune diseases
Riccardo Saccardi • 21 Oct 2023
View All Videos
3:28
The use of anti-CD19 CAR-T therapy for Richter’s transformation
Adam Kittai • 6 Oct 2023
1:09
Sequencing of therapies to improve outcomes of CLL patients
Martina Seiffert • 8 Oct 2023
1:08
Combining CAR-T with T cell-engaging bispecific antibodies to enhance efficacy in CLL murine models
Martina Seiffert • 8 Oct 2023
2:40
Results from the US Lymphoma CAR-T consortium on brexu-cel for R/R MCL in SoC practice
Yucai Wang • 8 Oct 2023
View All Videos
The content of VJHemOnc is intended for healthcare professionals